NCT00530010View on ClinicalTrials.gov

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions
Liver Cancer
Interventions
RADIATION

yttrium Y 90 glass microspheres

The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00530010 - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter